ALAB Form 4: Manuel Alba-Marquez executes 10b5-1 sales, trust holdings disclosed

Rhea-AI Filing Summary

Astera Labs director Manuel Alba-Marquez reported multiple sales of Company common stock on 09/02/2025 executed under a Rule 10b5-1 trading plan adopted May 29, 2025. The Form 4 lists a sequence of discrete dispositions at weighted-average prices in rising price bands (roughly $167.59–$180.53 per share) and states the resulting beneficial ownership figures held indirectly by the Alba Trust and Casa Alameda 2007, LLC. Following the reported transactions, the filing shows the Alba Trust's indirect holdings at 1,724,498 shares and Casa Alameda 2007, LLC's indirect holdings at 385,863 shares; the reporting person also notes 5,000 shares owned by a spouse.

Positive

• Sales executed under a Rule 10b5-1 trading plan, adopted May 29, 2025, indicating the transactions were pre-planned
• Weighted-average prices and price ranges are disclosed for each block, providing transparency on execution bands

Negative

• Substantial dispositions reported on 09/02/2025 that reduced Alba Trust's indirect holdings to 1,724,498 shares
• Casa Alameda 2007, LLC indirect holdings declined to 385,863 shares after the reported sales

Insights

Financial Analyst

TL;DR Significant scheduled insider sales executed via a 10b5-1 plan reduced indirect holdings but were pre-planned, limiting surprise to the market.

The Form 4 documents systematic disposals on a single date under a Rule 10b5-1 plan, with weighted-average prices disclosed across multiple transaction bands. For investors this clarifies that the sales were automated rather than ad hoc; the filing provides post-sale indirect ownership levels for the Alba Trust (1,724,498 shares) and Casa Alameda 2007, LLC (385,863 shares). No derivative transactions or additional pledges are reported. The disclosure allows reconciliation of insider liquidity but does not include total proceeds aggregated in the filing.

Corporate Governance Expert

TL;DR Use of a documented 10b5-1 plan provides procedural defensibility for the sales but still reduces insider concentration.

The filing explicitly states the trades occurred pursuant to a 10b5-1 plan adopted May 29, 2025, which is a governance best practice for scheduled insider sales to mitigate insider trading concerns. The report also includes standard disclaimers regarding trust and LLC ownership and supplies weighted-average price ranges for each block. The signature is by an attorney-in-fact, consistent with delegated execution. The disclosure is complete for the transactions reported; no amendments or option exercises are shown.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ALBA MANUEL

(Last) (First) (Middle)

C/O ASTERA LABS, INC.

2345 NORTH FIRST STREET

(Street)

SAN JOSE CA 95131

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Astera Labs, Inc. [ ALAB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/02/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/02/2025		S(1)		6,717	D	$168.2316(2)	1,867,781	I	By Alba Trust(3)
Common Stock	09/02/2025		S(1)		10,586	D	$168.9591(4)	1,857,195	I	By Alba Trust(3)
Common Stock	09/02/2025		S(1)		10,108	D	$170.1033(5)	1,847,087	I	By Alba Trust(3)
Common Stock	09/02/2025		S(1)		11,646	D	$171.1597(6)	1,835,441	I	By Alba Trust(3)
Common Stock	09/02/2025		S(1)		17,373	D	$172.0574(7)	1,818,068	I	By Alba Trust(3)
Common Stock	09/02/2025		S(1)		22,459	D	$173.1229(8)	1,795,609	I	By Alba Trust(3)
Common Stock	09/02/2025		S(1)		36,288	D	$174.018(9)	1,759,321	I	By Alba Trust(3)
Common Stock	09/02/2025		S(1)		4,006	D	$175.0424(10)	1,755,315	I	By Alba Trust(3)
Common Stock	09/02/2025		S(1)		9,622	D	$176.2324(11)	1,745,693	I	By Alba Trust(3)
Common Stock	09/02/2025		S(1)		13,475	D	$177.0325(12)	1,732,218	I	By Alba Trust(3)
Common Stock	09/02/2025		S(1)		1,870	D	$178.2163(13)	1,730,348	I	By Alba Trust(3)
Common Stock	09/02/2025		S(1)		3,262	D	$179.2464(14)	1,727,086	I	By Alba Trust(3)
Common Stock	09/02/2025		S(1)		2,588	D	$180.0993(15)	1,724,498	I	By Alba Trust(3)
Common Stock	09/02/2025		S(1)		1,478	D	$168.2315(2)	417,385	I	By Casa Alameda 2007, LLC(16)
Common Stock	09/02/2025		S(1)		2,329	D	$168.9591(4)	415,056	I	By Casa Alameda 2007, LLC(16)
Common Stock	09/02/2025		S(1)		2,224	D	$170.1033(5)	412,832	I	By Casa Alameda 2007, LLC(16)
Common Stock	09/02/2025		S(1)		2,562	D	$171.1598(6)	410,270	I	By Casa Alameda 2007, LLC(16)
Common Stock	09/02/2025		S(1)		3,822	D	$172.0574(7)	406,448	I	By Casa Alameda 2007, LLC(16)
Common Stock	09/02/2025		S(1)		4,941	D	$173.1229(8)	401,507	I	By Casa Alameda 2007, LLC(16)
Common Stock	09/02/2025		S(1)		7,983	D	$174.018(9)	393,524	I	By Casa Alameda 2007, LLC(16)
Common Stock	09/02/2025		S(1)		882	D	$175.0423(17)	392,642	I	By Casa Alameda 2007, LLC(16)
Common Stock	09/02/2025		S(1)		2,116	D	$176.2325(11)	390,526	I	By Casa Alameda 2007, LLC(16)
Common Stock	09/02/2025		S(1)		2,965	D	$177.0325(12)	387,561	I	By Casa Alameda 2007, LLC(16)
Common Stock	09/02/2025		S(1)		411	D	$178.2159(18)	387,150	I	By Casa Alameda 2007, LLC(16)
Common Stock	09/02/2025		S(1)		718	D	$179.2462(14)	386,432	I	By Casa Alameda 2007, LLC(16)
Common Stock	09/02/2025		S(1)		569	D	$180.0988(15)	385,863	I	By Casa Alameda 2007, LLC(16)
Common Stock								5,000	I	By spouse
Common Stock								2,351	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 29, 2025.

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $167.5900 to $168.5800, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. These shares are owned directly by Manuel Alba-Marquez in trust for Alba 2003 Living Trust (the "Alba Trust"), of which the Reporting Person and his spouse are co-trustees. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

4. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $168.5900 to $169.5800, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

5. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $169.5900 to $170.5800, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

6. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $170.5900 to $171.5800, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

7. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $171.5900 to $172.5800, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

8. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $172.5900 to $173.5800, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

9. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $173.5900 to $174.5700, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

10. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $174.6000 to $175.5800, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

11. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $175.6100 to $176.5900, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

12. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $176.6000 to $177.5800, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

13. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $177.7100 to $178.6900, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

14. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $178.7600 to $179.7400, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

15. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $179.7800 to $180.5300, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

16. These shares are owned directly by Casa Alameda 2007, LLC, of which the Reporting Person is a manager. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

17. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $174.6000 to $175.5700, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

18. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $177.7100 to $178.6700, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

	/s/ Philip Mazzara, Attorney-in-Fact	09/04/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Manuel Alba-Marquez report on Form 4 for ALAB?

The director reported multiple sales of Astera Labs common stock on 09/02/2025 executed pursuant to a Rule 10b5-1 trading plan adopted May 29, 2025.

Were the sales discretionary or part of a pre-arranged plan?

The filing states the sales occurred automatically pursuant to a Rule 10b5-1 trading plan, indicating they were pre-arranged.

What are the reported post-transaction holdings for Alba Trust and Casa Alameda 2007, LLC?

The Form 4 shows the Alba Trust's indirect holdings at 1,724,498 shares and Casa Alameda 2007, LLC's indirect holdings at 385,863 shares after the reported transactions.

What price ranges were the shares sold at?

The filing discloses weighted-average price bands for each block, with execution ranges cited roughly between $167.59 and $180.53 per share across the transactions.

Did the Form 4 report any derivative transactions or option exercises?

No. Table II for derivative securities contains no reported transactions; the filing only reports non-derivative common stock dispositions.